

# Epidemiology of the classical myeloproliferative neoplasia: an expansive and complex map

Blood Reviews

42, 100706

DOI: [10.1016/j.blre.2020.100706](https://doi.org/10.1016/j.blre.2020.100706)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Novel and combination therapies for polycythemia vera and essential thrombocythemia: the dawn of a new era. <i>Expert Review of Hematology</i> , 2020, 13, 1189-1199.	2.2	0
2	Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19. <i>Blood Cancer Journal</i> , 2021, 11, 21.	6.2	26
3	Inflammatory Microenvironment and Specific T Cells in Myeloproliferative Neoplasms: Immunopathogenesis and Novel Immunotherapies. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1906.	4.1	19
4	Overview of Myeloproliferative Neoplasms. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 159-176.	2.2	18
5	The Epidemiology of Myeloproliferative Neoplasms in New Zealand between 2010 and 2017: Insights from the New Zealand Cancer Registry. <i>Current Oncology</i> , 2021, 28, 1544-1557.	2.2	6
6	Epidemiology of the Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 177-189.	2.2	14
7	Emerging agents and regimens for polycythemia vera and essential thrombocythemia. <i>Biomarker Research</i> , 2021, 9, 40.	6.8	7
8	Myeloid-Derived Suppressor Cells and Mesenchymal Stem/Stromal Cells in Myeloid Malignancies. <i>Journal of Clinical Medicine</i> , 2021, 10, 2788.	2.4	15
9	Survival in Primary Myelofibrosis: A Population-based Analysis in the Netherlands. <i>HemaSphere</i> , 2021, 5, e595.	2.7	1
10	Patterns of Care for Older Patients With Myelofibrosis: A Population-based Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e551-e558.	0.4	3
11	Arterial hypertension assessment in a population with chronic myeloid leukemia. <i>Scientific Reports</i> , 2021, 11, 14637.	3.3	5
12	Subdural Hemorrhage Due to Acquired Von Willebrand Syndrome in a Patient With Polycythemia Vera. <i>Cureus</i> , 2021, 13, e16625.	0.5	0
13	Dislipemia en pacientes con enfermedades onco-hematológicas. <i>Endocrinología, Diabetes Y Nutrición</i> , 2021, 69, 446-446.	0.3	0
14	Integration of Molecular Information in Risk Assessment of Patients with Myeloproliferative Neoplasms. <i>Cells</i> , 2021, 10, 1962.	4.1	11
15	NK Cells in Myeloproliferative Neoplasms (MPN). <i>Cancers</i> , 2021, 13, 4400.	3.7	0
17	Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis: A Systematic Review and Meta-Analysis. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 873.e1-873.e13.	1.2	9
18	Tratamiento citorreductor disponible en Colombia para la trombocitemia esencial. Revisión panorámica de la evidencia. <i>Revista Colombiana De Hematología Y Oncología</i> , 2021, 8, 76-89.	0.0	0
19	Targeting Abnormal Hematopoietic Stem Cells in Chronic Myeloid Leukemia and Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms. <i>International Journal of Molecular Sciences</i> , 2021, 22, 659.	4.1	9

#	ARTICLE	IF	CITATIONS
20	A population-based study of outcomes in polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the United States from 2001 to 2015: Comparison with data from a Mayo Clinic single institutional series. <i>American Journal of Hematology</i> , 2021, 96, E464-E468.	4.1	9
21	Real-world survival of US patients with intermediate- to high-risk myelofibrosis: impact of ruxolitinib approval. <i>Annals of Hematology</i> , 2022, 101, 131-137.	1.8	20
22	Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States. <i>Leukemia and Lymphoma</i> , 2022, 63, 694-702.	1.3	22
23	Loss of <i>Atg2b</i> and <i>Gskip</i> Impairs the Maintenance of the Hematopoietic Stem Cell Pool Size. <i>Molecular and Cellular Biology</i> , 2022, 42, MCB0002421.	2.3	3
24	Contemporary practice patterns of tyrosine kinase inhibitor use among older patients with chronic myeloid leukemia in the United States. <i>Therapeutic Advances in Hematology</i> , 2021, 12, 204062072110434.	2.5	3
25	The Prevalence of Myeloproliferative Disorders in A Group of Iraqi Patients And Its Relation To Blood Indices Parameters. <i>Open Access Macedonian Journal of Medical Sciences</i> , 2020, 8, 660-665.	0.2	0
26	Mobile App Intervention on Reducing the Myeloproliferative Neoplasm Symptom Burden: Pilot Feasibility and Acceptability Study. <i>JMIR Formative Research</i> , 2022, 6, e33581.	1.4	4
27	Red Blood Cell Morphodynamics in Patients with Polycythemia Vera and Stroke. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2247.	4.1	7
28	PEDF reduces malignant cells proliferation and inhibits the progression of myelofibrosis in myeloproliferative neoplasms. <i>Biochemical Pharmacology</i> , 2022, 199, 115013.	4.4	2
29	Covert Brain Infarcts in Patients with Philadelphia Chromosome-Negative Myeloproliferative Disorders. <i>Journal of Clinical Medicine</i> , 2022, 11, 13.	2.4	2
30	Blast and accelerated phase CML: room for improvement. <i>Hematology American Society of Hematology Education Program</i> , 2021, 2021, 122-128.	2.5	13
31	Dyslipidaemia in patients with haematology/oncology diseases. <i>Endocrinologia y Nutrición (English Ed)</i> , 2022, 69, 446-450.	0.2	0
32	Advances in Risk Stratification and Treatment of Polycythemia Vera and Essential Thrombocythemia. <i>Current Hematologic Malignancy Reports</i> , 2022, 17, 155-169.	2.3	12
33	Healthcare resource utilization in patients with myeloproliferative neoplasms: A Danish nationwide matched cohort study. <i>European Journal of Haematology</i> , 0, , .	2.2	2
34	Research Progress of BCR-ABL Negative MPN. <i>Advances in Clinical Medicine</i> , 2022, 12, 8337-8341.	0.0	0
35	Towards a Personalized Definition of Prognosis in Philadelphia-Negative Myeloproliferative Neoplasms. <i>Current Hematologic Malignancy Reports</i> , 2022, 17, 127-139.	2.3	5
36	Age-related macular degeneration and myeloproliferative neoplasms – A common pathway. <i>Acta Ophthalmologica</i> , 2022, 100, 3-35.	1.1	3
37	JAK2V617F variant allele frequency, non-driver mutations, single-nucleotide variants and polycythemia vera outcome. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	2.5	2

#	ARTICLE	IF	CITATIONS
38	The Contribution of JAK2 46/1 Haplotype in the Predisposition to Myeloproliferative Neoplasms. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12582.	4.1	4
39	The Manifestation of a Patient With Myelofibrosis in 68Ga-DOTA-FAPI-04 PET/CT Mimicking "Super Bone Imaging": <i>Clinical Nuclear Medicine</i> , 2022, 47, 1056-1058.	1.3	0
40	Survival trends in hematological malignancies in the Nordic countries through 50 years. <i>Blood Cancer Journal</i> , 2022, 12, .	6.2	9
41	Identification of microRNA editing sites in three subtypes of leukemia. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	3.5	2
42	Real-world treatments and thrombotic events in polycythemia vera patients in the USA. <i>Annals of Hematology</i> , 2023, 102, 571-581.	1.8	5
43	Myeloid/lymphoid neoplasm with eosinophilia and BCR/FGFR1 rearrangement with transformation to cortical T-lymphoblastic lymphoma and erythroid precursors: a case report. <i>Journal of Medical Case Reports</i> , 2023, 17, .	0.8	1
44	Outcomes of SARS-CoV-2 infection in Ph-neg chronic myeloproliferative neoplasms: results from the EPICOVIDEHA registry. <i>Therapeutic Advances in Hematology</i> , 2023, 14, 204062072311547.	2.5	3
45	Older patients with chronic myeloid leukemia face suboptimal molecular testing and tyrosine kinase inhibitor adherence. <i>Blood Advances</i> , 0, , .	5.2	1
46	Cytological Diagnosis of Classic Myeloproliferative Neoplasms at the Age of Molecular Biology. <i>Cells</i> , 2023, 12, 946.	4.1	2
47	Novel therapeutic strategies for essential thrombocythemia/polycythemia vera. <i>Blood Research</i> , 2023, 58, S83-S89.	1.3	1
48	Anticoagulant treatment for pediatric splanchnic vein thrombosis: a systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2023, , .	3.8	0
49	ÅŇanak kale onsekiz mart ÅŇ4niversitesi hematoloji bilim dalÄ±na baÅŇvuran hematolojik maligniteli hastalarÄ±n retrospektif olarak deÅŇlendirilmesi. , 0, , .		0
50	Hip and Knee Osteoarthritis in Patients with Chronic Myeloproliferative Neoplasms: A Cross-Sectional Study. <i>Life</i> , 2023, 13, 1388.	2.4	2
51	Regional features of the incidence of chronic Ph-negative myeloproliferative neoplasms in Belarus. , 2023, , 67-74.		0
52	High molecular risk variants, severe thrombocytopenia and large unstained cells count affect the outcome in primary myelofibrosis. <i>Journal of Applied Genetics</i> , 2023, 64, 479-491.	1.9	0
53	Mesenchymal stromal cells in myeloid malignancies: Immunotherapeutic opportunities. <i>Heliyon</i> , 2024, 10, e25081.	3.2	0
54	Insights into the role of JAK2-I724T variant in myeloproliferative neoplasms from a unique cohort of New Zealand patients. <i>Hematology</i> , 2024, 29, .	1.5	0